Fernandes, M. G. O.Vilariça, A. S.Fernandes, B.Camacho, C.Saraiva, C.Estevinho, F.Bastos, H. Novais eLopes, J. M.Fidalgo, P.Garrido, P.Alves, S.Silva, S.Sequeira, T.Barata, F.2024-12-112024-12-112024-012531-0437http://hdl.handle.net/10400.1/26447The management of NSCLC remains challenging, and the integration of data from predictive biomarkers in routine clinical practice can contribute to an optimal, individualized patient approach, particularly given the rapid emergence of effective targeted therapies. When considering molecular biomarker testing, the choice of the biomarker panel, target population, testing approach, and turnaround time are key issues that, when properly addressed, can improve the survival outcomes of NSCLC patients.engOf American PathologistsTesting GuidelineAcquire resistanceClinical OncologyEGFR mutationAssociationCollegeSelectionNSCLCALKjournal article10.1016/j.pulmoe.2022.11.009